Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LYNPARZA Tablets 100 mg, 150mg General Drug Use-results Study in Patients on Maintenance Treatment After Platinum-based Chemotherapy for BRCA Mutated Curatively Unresectable Pancreas Cancer

NCT04889404 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04889404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04889404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LYNPARZA Tablets 100 mg, 150mg General Drug Use-results Study in Patients on Maintenance Treatment After Platinum-based Chemotherapy for BRCA Mutated Curatively Unresectable Pancreas Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 22, 2021
Completion date
February 6, 2025
Enrollment
130 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms